Zuellig Pharma Unveils Lilly's Breakthrough Obesity and Diabetes Treatment in Thailand
BANGKOK, THAILAND - According to a press release from Media OutReach Newswire dated May 27, 2025, Zuellig Pharma, a prominent provider of healthcare solutions across Asia, has declared that they will be introducing Mounjaro ® (Tirzepatide), the groundbreaking medication for obesity and diabetes developed by Eli Lilly and Company, is set to launch in Thailand by late May 2025. Zuellig Pharma has obtained the marketing authorization for Mounjaro. ® (tirzepatide) in Thailand, after obtaining the distribution and promotional authorization for the drug from Eli Lilly and Company earlier this year.
Mounjaro ® (Tirzepatide) is a weekly prescription medication intended for use in treating adults who have not adequately managed their Type 2 Diabetes through lifestyle changes like diet and exercise. It can be used alone when metformin cannot be tolerated or has contraindications, alongside other medications for diabetes care. Additionally, it serves as part of a regimen involving calorie restriction and enhanced physical activity aimed at managing body weight, which includes both losing and maintaining weight, particularly in adults starting with a Body Mass Index (BMI) of 30 kg/m² or higher. 2 (obesity) or ≥27 kg/m² to < 30 kg/m² 2 (including those who have obesity) with at least one related metabolic complication (such as high blood pressure, abnormal cholesterol levels, sleep apnea, heart disease, pre-diabetes, or type 2 diabetes).
The availability of Mounjaro ® (Tirzepatide) represents a major step forward in managing both obesity and type 2 diabetes, providing a singular drug option delivered via a user-friendly pre-filled pen. Mounjaro ® KwikPen ® (Tirzepatide injection) comes in dosages of 2.5 mg, 5 mg, 7.5 mg, and 10 mg, allowing healthcare providers to tailor treatment plans more effectively to address each patient's specific requirements.
Obesity is a significant public health issue in Thailand, impacting 48% of the overall population. 2 The Ministry of Public Health classifies obesity as a Non-Communicable Disease (NCD) due to its strong link to rising rates for chronic illnesses, particularly type 2 diabetes. In 2024, the Department of Disease Control reported that 1 in 10 Thai individuals – a total of 6.5 million people – suffer from type 2 diabetes, impacting their physical, mental, and social well-being. 2
Individuals dealing with diabetes encounter substantial difficulties in controlling their glucose levels and avoiding complications like heart diseases, long-term renal issues, vision problems due to diabetes, and foot sores associated with diabetes, potentially resulting in serious infections and even amputations. 3
Obesity and diabetes have emerged as major health concerns in Thailand, and we are thrilled to speed up the accessibility of Mounjaro. ® (Tirzepatide) for patients in the region. Given our extensive knowledge of the local regulatory environment and our successful history of providing cutting-edge healthcare solutions in underserved medical fields, we are ideally positioned to improve the accessibility of this medication in the market. This marks an important advancement in our dedication to enhancing access to healthcare, notably within the realm of chronic metabolic diseases,” stated Rehan Saghir, who serves as the Executive Vice President overseeing commercial activities at Zuellig Pharma.
For more information, visit: https://www.zuelligpharma.com/
Provided by SyndiGate Media Inc. Syndigate.info ).
Post a Comment for "Zuellig Pharma Unveils Lilly's Breakthrough Obesity and Diabetes Treatment in Thailand"